Skip to main content
Top
Published in: Annals of Nuclear Medicine 11/2022

15-08-2022 | Positron Emission Tomography | Original Article

PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model

Authors: Motofumi Suzuki, Takuma Matsuda, Kohei Nakajima, Yuta Yokouchi, Yuji Kuge, Mikako Ogawa

Published in: Annals of Nuclear Medicine | Issue 11/2022

Login to get access

Abstract

Objective

We previously reported that alterations of the tumor microenvironment (TME) by programmed death receptor-1 (PD1) blockade affected tumor glucose metabolism and tumor 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake. In cancer cells, high glycolysis allows cells to sustain rapid proliferation since glycolysis is closely related to the proliferation of cancer cells. Therefore, imaging of cellular proliferation may provide more detail of TME alterations. In this study, we investigated how TME alterations by PD1 blockade affects the uptake of 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), which is a 18F-radiolabeled thymidine derivative and is taken up by proliferating cells.

Methods

Mice inoculated with murine colon carcinoma CT26 cells were intraperitoneally administered an anti-PD1 antibody on Day 0, when the tumor volume exceeded 50 mm3, and Day 5. [18F]FLT-PET imaging was performed pre-treatment (Day 0) and post treatment (Day 7). Tumor infiltrating lymphocytes (TILs) were identified by flow cytometry. [18F]FLT accumulation and localization in tumor tissue was evaluated by autoradiography and immunohistochemistry. The cell-cycle distribution of tumors and CT26 cells exposed to cytokines (interleukin-2, interferon [INF]-γ, and tumor necrosis factor [TNF]-α) was analyzed by flow cytometry.

Results

PD1 blockade increased CD8+ and CD4+ T cells in tumor tissue and significantly suppressed tumor proliferation; however, tumor [18F]FLT uptake remained unchanged. Autoradiography and immunohistochemistry showed that [18F]FLT was mainly taken up by cancer cells, but not TILs. Flow cytometric analysis demonstrated that the population of cells in G2/M phase increased after PD1 blockade. Moreover, INF-γ and TNF-α significantly increased cells in G2/M phase in vitro.

Conclusion

PD1 blockade-induced alteration of the TME increased CT26 tumor cells in the G2/M phase, which have high thymidine kinase 1 activity. Therefore, [18F]FLT is taken up by tumor cells even if tumor proliferation is suppressed. This observation may be useful for evaluating the response to immunotherapy.
Literature
1.
go back to reference Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600.CrossRef Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600.CrossRef
2.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
3.
go back to reference Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRef Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.CrossRef
4.
go back to reference Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rubenthaler J, et al. PET/CT imaging for tumor response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4:63.CrossRef Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rubenthaler J, et al. PET/CT imaging for tumor response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4:63.CrossRef
5.
go back to reference Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumor response to immunotherapy. Eur Radiol Exp. 2020;4:2.CrossRef Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumor response to immunotherapy. Eur Radiol Exp. 2020;4:2.CrossRef
6.
go back to reference Bollineni VR, Collette S, Liu Y. Functional and molecular imaging in cancer drug development. Chin Clin Oncol. 2014;3:17.PubMed Bollineni VR, Collette S, Liu Y. Functional and molecular imaging in cancer drug development. Chin Clin Oncol. 2014;3:17.PubMed
7.
go back to reference Tomita M, Yasui H, Higashikawa K, Nakajima K, Takakura H, Shiga T, et al. Anti PD-1 treatment increases [(18)F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Res. 2018;8:82.CrossRef Tomita M, Yasui H, Higashikawa K, Nakajima K, Takakura H, Shiga T, et al. Anti PD-1 treatment increases [(18)F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Res. 2018;8:82.CrossRef
8.
go back to reference Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, et al. Influence on [(18)F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 2020;10:24.CrossRef Tomita M, Suzuki M, Kono Y, Nakajima K, Matsuda T, Kuge Y, et al. Influence on [(18)F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Res. 2020;10:24.CrossRef
9.
go back to reference Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.CrossRef Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.CrossRef
10.
go back to reference Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6.CrossRef Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6.CrossRef
11.
go back to reference Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ. A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81–97.CrossRef Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ. A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81–97.CrossRef
12.
go back to reference Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, et al. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J Nucl Med. 2014;55:1069–74.CrossRef Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, et al. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J Nucl Med. 2014;55:1069–74.CrossRef
13.
go back to reference Yun M, Oh SJ, Ha HJ, Ryu JS, Moon DH. High radiochemical yield synthesis of 3’-deoxy-3’-[18F]fluorothymidine using (5’-O-dimethoxytrityl-2’-deoxy-3’-O-nosyl-beta-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol. 2003;30:151–7.CrossRef Yun M, Oh SJ, Ha HJ, Ryu JS, Moon DH. High radiochemical yield synthesis of 3’-deoxy-3’-[18F]fluorothymidine using (5’-O-dimethoxytrityl-2’-deoxy-3’-O-nosyl-beta-D-threo pentofuranosyl)thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol. 2003;30:151–7.CrossRef
14.
go back to reference Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7.PubMed Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7.PubMed
15.
go back to reference Lai WY, Huang BT, Wang JW, Lin PY, Yang PC. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects. Mol Ther Nucleic Acids. 2016;5: e397.CrossRef Lai WY, Huang BT, Wang JW, Lin PY, Yang PC. A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects. Mol Ther Nucleic Acids. 2016;5: e397.CrossRef
16.
go back to reference Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3’-fluoro-3’-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A. 2011;108:18396–9.CrossRef Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3’-fluoro-3’-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A. 2011;108:18396–9.CrossRef
17.
go back to reference Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340–6.CrossRef Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340–6.CrossRef
18.
go back to reference Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350–8.CrossRef Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 1988;263:8350–8.CrossRef
19.
go back to reference Roppongi M, Izumisawa M, Terasaki K, Muraki Y, Shozushima M. (18)F-FDG and (11)C-choline uptake in proliferating tumor cells is dependent on the cell cycle in vitro. Ann Nucl Med. 2019;33:237–43.CrossRef Roppongi M, Izumisawa M, Terasaki K, Muraki Y, Shozushima M. (18)F-FDG and (11)C-choline uptake in proliferating tumor cells is dependent on the cell cycle in vitro. Ann Nucl Med. 2019;33:237–43.CrossRef
20.
go back to reference Sung Y, Tetrault MA, Takahashi K, Ouyang J, Pratx G, Fakhri GE, et al. Dependence of fluorodeoxyglucose (FDG) uptake on cell cycle and dry mass: a single-cell study using a multi-modal radiography platform. Sci Rep. 2020;10:4280.CrossRef Sung Y, Tetrault MA, Takahashi K, Ouyang J, Pratx G, Fakhri GE, et al. Dependence of fluorodeoxyglucose (FDG) uptake on cell cycle and dry mass: a single-cell study using a multi-modal radiography platform. Sci Rep. 2020;10:4280.CrossRef
21.
go back to reference Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, et al. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene. 2000;19:514–25.CrossRef Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, Dou QP, et al. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene. 2000;19:514–25.CrossRef
22.
go back to reference Burke F, East N, Upton C, Patel K, Balkwill FR. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer. 1997;33:1114–21.CrossRef Burke F, East N, Upton C, Patel K, Balkwill FR. Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer. 1997;33:1114–21.CrossRef
23.
go back to reference Faurschou A, Gniadecki R, Calay D, Wulf HC. TNF-alpha impairs the S-G2/M cell cycle checkpoint and cyclobutane pyrimidine dimer repair in premalignant skin cells: role of the PI3K-Akt pathway. J Invest Dermatol. 2008;128:2069–77.CrossRef Faurschou A, Gniadecki R, Calay D, Wulf HC. TNF-alpha impairs the S-G2/M cell cycle checkpoint and cyclobutane pyrimidine dimer repair in premalignant skin cells: role of the PI3K-Akt pathway. J Invest Dermatol. 2008;128:2069–77.CrossRef
Metadata
Title
PD1 blockade alters cell-cycle distribution and affects 3′-deoxy-3′-[18F]fluorothymidine uptake in a mouse CT26 tumor model
Authors
Motofumi Suzuki
Takuma Matsuda
Kohei Nakajima
Yuta Yokouchi
Yuji Kuge
Mikako Ogawa
Publication date
15-08-2022
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 11/2022
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-022-01782-0

Other articles of this Issue 11/2022

Annals of Nuclear Medicine 11/2022 Go to the issue